sodium;(2S)-2-[(2R)-3-hexadecanoyloxy-4-hydroxy-5-oxo-2H-furan-2-yl]-2-sulfinooxyethanolate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: sodium;(2S)-2-[(2R)-3-hexadecanoyloxy-4-hydroxy-5-oxo-2H-furan-2-yl]-2-sulfinooxyethanolate
• 化学式: C22H37NaO9S
• 分子量: 500.6
• InChiKey: ZODCPMBSLDDCLK-YFUYRHFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.59
• 重原子数：
  33
• 可旋转键数：
  20
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  162
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• OLIGONUCLEOTIDE FORMULATION
  申请人：Regado Biosciences Inc.

  公开号：EP2928903A1

  公开（公告）日：2015-10-14
• [EN] OLIGONUCLEOTIDE FORMULATION<br/>[FR] FORMULATION D'OLIGONUCLÉOTIDE
  申请人：NOVAMEDICA LTD LIABILITY COMPANY

  公开号：WO2014089484A1

  公开（公告）日：2014-06-12

  The present invention relates generally to pharmaceutical formulations of conjugated oligonucleotides, such as pegylated aptamers, as well as to a method of preparing and using the same. The pharmaceutical formulations have desirable shelf life characteristics under varied storage conditions. Formulations of oligonucleotides or oligonucleotides conjugates and methods for their preparation and use are provided having a shelf life of at least about 24 months or, more preferably, at least about 36 months at about 2 to about 30°C. In particular embodiments, the formulations have a pH of about 7 or less and contain methionine. Optionally, dissolved oxygen content is reduced during the manufacturing process is used to improve desired shelf life characteristics.